{
    "id": 26982,
    "fullName": "TNFAIP3 Q143*",
    "impact": "nonsense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "TNFAIP3 Q143* results in a premature truncation of the Tnfaip3 protein at amino acid 143 of 790 (UniProt.org). Q143* has not been biochemically characerized however, is predicted to results in a loss of Tnfaip3 protein function due to the loss of a majority of the functional domains (UniProt.ort), and also has been associated with resistance to BTK inhibitors in culture (PMID: 28178345).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7128,
        "geneSymbol": "TNFAIP3",
        "terms": [
            "TNFAIP3",
            "A20",
            "AISBL",
            "OTUD7C",
            "TNFA1P2"
        ]
    },
    "variant": "Q143*",
    "createDate": "09/11/2017",
    "updateDate": "06/30/2018",
    "referenceTranscriptCoordinates": {
        "id": 174362,
        "transcript": "NM_001270508",
        "gDna": "chr6:g.137874976C>T",
        "cDna": "c.427C>T",
        "protein": "p.Q143*",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11874,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cells that acquired resistance to Imbruvica (ibrutinib) harbored the TNFAIP3 Q143* mutation, and was resistant to Zydelig (idelalisib) in culture (PMID: 28178345).",
            "molecularProfile": {
                "id": 28333,
                "profileName": "TNFAIP3 Q143*"
            },
            "therapy": {
                "id": 1023,
                "therapyName": "Idelalisib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11873,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cells with acquired resistance to Imbruvica (ibrutinib) harbored the TNFAIP3 Q143* variant and were resistant to ONO-4059 in culture (PMID: 28178345).",
            "molecularProfile": {
                "id": 28333,
                "profileName": "TNFAIP3 Q143*"
            },
            "therapy": {
                "id": 2691,
                "therapyName": "ONO-4059",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11879,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zydelig (idelalisib) and ONO-4059, in combination, inhibited growth of diffuse large B-cell lymphoma cells harboring TNFAIP3 Q143* with acquired resistance to Imbruvica (ibrutinib), in culture (PMID: 28178345).",
            "molecularProfile": {
                "id": 28333,
                "profileName": "TNFAIP3 Q143*"
            },
            "therapy": {
                "id": 6199,
                "therapyName": "Idelalisib + ONO-4059",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11869,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the TNFAIP3 Q143* mutation was identified in diffuse large B-cell lymphoma cells that acquired resistance to Imbruvica (ibrutinib) in culture (PMID: 28178345).",
            "molecularProfile": {
                "id": 28333,
                "profileName": "TNFAIP3 Q143*"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9819,
                    "pubMedId": 28178345,
                    "title": "PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178345"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28333,
            "profileName": "TNFAIP3 Q143*",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 174363,
            "transcript": "NM_001270507",
            "gDna": "chr6:g.137874976C>T",
            "cDna": "c.427C>T",
            "protein": "p.Q143*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 174364,
            "transcript": "NM_006290",
            "gDna": "chr6:g.137874976C>T",
            "cDna": "c.427C>T",
            "protein": "p.Q143*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 174366,
            "transcript": "XM_005267119",
            "gDna": "chr6:g.137874976C>T",
            "cDna": "c.427C>T",
            "protein": "p.Q143*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 174365,
            "transcript": "XM_011536096",
            "gDna": "chr6:g.137874976C>T",
            "cDna": "c.427C>T",
            "protein": "p.Q143*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 174361,
            "transcript": "XM_011536095",
            "gDna": "chr6:g.137874976C>T",
            "cDna": "c.427C>T",
            "protein": "p.Q143*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 174362,
            "transcript": "NM_001270508",
            "gDna": "chr6:g.137874976C>T",
            "cDna": "c.427C>T",
            "protein": "p.Q143*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}